MA35351B1 - Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. - Google Patents

Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.

Info

Publication number
MA35351B1
MA35351B1 MA36755A MA36755A MA35351B1 MA 35351 B1 MA35351 B1 MA 35351B1 MA 36755 A MA36755 A MA 36755A MA 36755 A MA36755 A MA 36755A MA 35351 B1 MA35351 B1 MA 35351B1
Authority
MA
Morocco
Prior art keywords
diabetes
novel
treatment
derivative useful
tetrahydroquinoline derivative
Prior art date
Application number
MA36755A
Other languages
English (en)
Inventor
Chafiq Hamdouchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35351(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA35351B1 publication Critical patent/MA35351B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un composé de la formule ci-dessous ou un sel pharmaceutique de celui-ci, des méthodes de traitement du diabète utilisant le composé ainsi qu'un procédé de préparation du composé.
MA36755A 2011-08-17 2014-02-13 Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. MA35351B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524462P 2011-08-17 2011-08-17
PCT/US2012/050051 WO2013025424A1 (fr) 2011-08-17 2012-08-09 Nouveau dérivé de 1,2,3,4-tetrahydroquinoline utile dans le traitement du diabète

Publications (1)

Publication Number Publication Date
MA35351B1 true MA35351B1 (fr) 2014-08-01

Family

ID=46690732

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36755A MA35351B1 (fr) 2011-08-17 2014-02-13 Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.

Country Status (30)

Country Link
US (1) US8431706B2 (fr)
EP (1) EP2744806B1 (fr)
JP (1) JP5903162B2 (fr)
KR (1) KR101570624B1 (fr)
CN (1) CN103687856B (fr)
AP (1) AP3589A (fr)
AR (1) AR087451A1 (fr)
AU (1) AU2012295372A1 (fr)
BR (1) BR112014003079A2 (fr)
CA (1) CA2843474C (fr)
CL (1) CL2014000357A1 (fr)
CO (1) CO6880069A2 (fr)
CR (1) CR20140052A (fr)
DO (1) DOP2014000018A (fr)
EA (1) EA022165B1 (fr)
EC (1) ECSP14013211A (fr)
ES (1) ES2578165T3 (fr)
GT (1) GT201400022A (fr)
IL (1) IL230635A (fr)
IN (1) IN2014MN00191A (fr)
MA (1) MA35351B1 (fr)
MX (1) MX2014001832A (fr)
PE (1) PE20140831A1 (fr)
PH (1) PH12014500366A1 (fr)
SG (1) SG11201401793PA (fr)
TN (1) TN2014000058A1 (fr)
TW (1) TWI537262B (fr)
UA (1) UA110983C2 (fr)
WO (1) WO2013025424A1 (fr)
ZA (1) ZA201400705B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014372114A1 (en) 2013-11-14 2016-06-09 Cadila Healthcare Limited Novel heterocyclic compounds
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (fr) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Composés antidiabétiques
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
MX2020007283A (es) 2018-01-08 2020-09-10 Celon Pharma Sa Derivados de acido 3-fenil-4-hexinoico como agonistas del receptor acoplado a la proteina g-40.
WO2019160882A1 (fr) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Inhibiteurs pd -1/pd-l1
WO2019204609A1 (fr) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Inhibiteurs pd-1/pd-l1
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
CN113906015B (zh) 2019-05-31 2024-03-01 现代药品株式会社 3-(4-(苄氧基)苯基)己-4-炔酸衍生物的新晶型
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
EP4052790A4 (fr) * 2019-10-31 2023-12-27 China Petroleum & Chemical Corporation Catalyseur supporté, son procédé de préparation et son application
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ,インク. Ampkアクチベーター
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
KR102699076B1 (ko) * 2021-04-01 2024-08-27 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도
CN115317484B (zh) * 2022-08-26 2023-07-18 北京箭牧科技有限公司 Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用
CN115671105B (zh) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Ly2922470在制备预防或治疗肾脏疾病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
DE60205234T2 (de) * 2001-03-27 2006-05-24 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
EA011010B1 (ru) * 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
EP1726580A4 (fr) * 2004-03-15 2008-02-13 Takeda Pharmaceutical Derive de l'acide aminophnylpropano
EP1731505B1 (fr) * 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Dérivés de l'acide alkoxyphénylpropanoïque
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR078948A1 (es) * 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
TWI537262B (zh) 2016-06-11
CR20140052A (es) 2014-06-20
SG11201401793PA (en) 2014-09-26
BR112014003079A2 (pt) 2017-02-21
EP2744806B1 (fr) 2016-04-27
EP2744806A1 (fr) 2014-06-25
CA2843474C (fr) 2015-12-15
UA110983C2 (uk) 2016-03-10
WO2013025424A1 (fr) 2013-02-21
JP2014521744A (ja) 2014-08-28
ECSP14013211A (es) 2014-03-31
CN103687856A (zh) 2014-03-26
ES2578165T3 (es) 2016-07-21
EA022165B1 (ru) 2015-11-30
KR20140041835A (ko) 2014-04-04
IL230635A (en) 2015-11-30
TN2014000058A1 (en) 2015-07-01
DOP2014000018A (es) 2014-04-15
US8431706B2 (en) 2013-04-30
TW201319060A (zh) 2013-05-16
KR101570624B1 (ko) 2015-11-19
AP2014007436A0 (en) 2014-02-28
AU2012295372A1 (en) 2014-01-23
US20130045990A1 (en) 2013-02-21
PH12014500366A1 (en) 2014-04-14
CN103687856B (zh) 2015-07-22
PE20140831A1 (es) 2014-07-14
AP3589A (en) 2016-02-15
ZA201400705B (en) 2015-11-25
MX2014001832A (es) 2014-02-27
JP5903162B2 (ja) 2016-04-13
CL2014000357A1 (es) 2014-09-05
CO6880069A2 (es) 2014-02-28
IN2014MN00191A (fr) 2015-08-21
GT201400022A (es) 2015-01-16
CA2843474A1 (fr) 2013-02-21
NZ621248A (en) 2015-08-28
IL230635A0 (en) 2014-03-31
EA201490269A1 (ru) 2014-05-30
AR087451A1 (es) 2014-03-26

Similar Documents

Publication Publication Date Title
MA35351B1 (fr) Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.
MA33840B1 (fr) Nouveau composé de spiropipéridine
MA35432B1 (fr) Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial
JOP20210064A1 (ar) عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
MA33662B1 (fr) Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
MA44721A (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA35623B1 (fr) Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives
IN2014MN02106A (fr)
MA37888A1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
MA38333A1 (fr) Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
MA38227B1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ß-lactamase
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA37405A1 (fr) Composés hétérocyclyle
EA201491933A1 (ru) Дигидрат соединения бензотиофена или его соли и способ его получения
MA39048B1 (fr) Nouveaux inhibiteurs de la dgat2
MA40895B1 (fr) Synthèse de copanlisib et son sel de dichlorhydrate
EA201491747A1 (ru) Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
JOP20130213B1 (ar) معارضات لمستقبلht3-5
TN2012000620A1 (fr) Procede de preparation du sel de l-arginine du perindopril